Characterization of BoHV-5 field strains circulation and report of transient specific subtype of bovine herpesvirus 5 in Argentina

<p>Abstract</p> <p>Background</p> <p>Bovine herpesvirus 5 (BoHV-5) is a member of the subfamily <it>Alphaherpesvirinae </it>responsible for meningo-encephalitis in young cattle. The first case of bovine meningo-encephalitis associated with a herpesvirus infection was reported in Australia. The current geographical distribution of BoHV-5 infection is mainly restricted to South America, especially Brazil and Argentina. Outbreaks of BoHV-5 are regularly observed in Argentina suggesting the circulation of the virus in the bovine population.</p> <p>Results</p> <p>Seventeen field strains of BoHV-5 isolated from 1984 to now were confirmed by differential PCR and subjected to restriction endonuclease analysis (REA). Viral DNA was cleaved with BstEII which allows the differentiation among subtypes a, b and non a, non b. According to the REA with BstEII, only one field strain showed a pattern similar to the Argentinean A663 strain (prototype of BoHV-5b). All other isolates showed a clear pattern similar to the Australian N569 strain (prototype of BoHV-5a) consistent with the subtypes observed in Brazil, the other South-American country where BoHV-5 is known to be prevalent. The genomic region of subtype b responsible for the distinct pattern was determined and amplified by PCR; specifically a point mutation was identified in glycoprotein B gene, on the BstEII restriction site, which generates the profile specific of BoHV-5b.</p> <p>Conclusions</p> <p>This is the first report of circulation of BoHV-5a in Argentina as the prevailing subtype. Therefore the circulation of BoHV-5b was restricted to a few years in Argentina, speculating that this subtype was not able to be maintained in the bovine population. The mutation in the gB gene is associated with the difference in the restriction patterns between subtypes "a" and "b".</p

Genetics Unveil the Genealogical Ancestry and Physical Appearance of an Unknown Historical Figure: Lady Leonor of Castile (Spain) (1256–1275)

Through this study, it has been possible to establish an accurate prediction of the physical characteristics, biogeographical origin, and genealogical ancestry of a previously obscured historical figure: The Princess Lady Leonor of Castile (1256–1275), one of the legitimate daughters of the Spanish King Alfonso X “The Wise”. The genetic analysis of External Visible Characteristics in the mummified remains attributed to this Princess has allowed determining her origin by mitochondrial and nuclear DNA analysis, and her physical appearance for hair, eyes, and skin color by autosomal SNPs. The results show that the mummified remains correspond to a young European woman with black hair, green-hazel eyes, and white skin. Her physical appearance has not been possible to be compared with any pictorial source, but the biogeographical analysis results are consistent with the historiographic genealogical information

Genetics unveil the genealogical ancestry and physical appearance of an unknown historical figure: lady Leonor of Castile (Spain) (1256–1275)

2023 Descuento MDPIThrough this study, it has been possible to establish an accurate prediction of the physical characteristics, biogeographical origin, and genealogical ancestry of a previously obscured historical figure: The Princess Lady Leonor of Castile (1256–1275), one of the legitimate daughters of the Spanish King Alfonso X “The Wise”. The genetic analysis of External Visible Characteristics in the mummified remains attributed to this Princess has allowed determining her origin by mitochondrial and nuclear DNA analysis, and her physical appearance for hair, eyes, and skin color by autosomal SNPs. The results show that the mummified remains correspond to a young European woman with black hair, green-hazel eyes, and white skin. Her physical appearance has not been possible to be compared with any pictorial source, but the biogeographical analysis results are consistent with the historiographic genealogical information.Depto. de Medicina Legal, Psiquiatría y PatologíaFac. de MedicinaTRUEpubDescuento UC

Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.

The incidence and outcomes of coronavirus disease 2019 (COVID-19) in immunocompromised patients are a matter of debate. We performed a prospective nationwide study including a consecutive cohort of liver transplant patients with COVID-19 recruited during the Spanish outbreak from 28 February to 7 April, 2020. The primary outcome was severe COVID-19, defined as the need for mechanical ventilation, intensive care, and/or death. Age- and gender-standardised incidence and mortality ratios (SIR and SMR) were calculated using data from the Ministry of Health and the Spanish liver transplant registry. Independent predictors of severe COVID-19 among hospitalised patients were analysed using multivariate Cox regression. A total of 111 liver transplant patients were diagnosed with COVID-19 (SIR = 191.2 [95% CI 190.3-192.2]). The epidemiological curve and geographic distribution overlapped widely between the liver transplant and general populations. After a median follow-up of 23 days, 96 patients (86.5%) were admitted to hospital and 22 patients (19.8%) required respiratory support. A total of 12 patients were admitted to the ICU (10.8%). The mortality rate was 18%, which was lower than in the matched general population (SMR = 95.5 [95% CI 94.2-96.8]). Overall, 35 patients (31.5%) met criteria of severe COVID-19. Baseline immunosuppression containing mycophenolate was an independent predictor of severe COVID-19 (relative risk = 3.94; 95% CI 1.59-9.74; p = 0.003), particularly at doses higher than 1,000 mg/day (p = 0.003). This deleterious effect was not observed with calcineurin inhibitors or everolimus and complete immunosuppression withdrawal showed no benefit. Being chronically immunosuppressed, liver transplant patients have an increased risk of acquiring COVID-19 but their mortality rates are lower than the matched general population. Upon hospital admission, mycophenolate dose reduction or withdrawal could help in preventing severe COVID-19. However, complete immunosuppression withdrawal should be discouraged. In liver transplant patients, chronic immunosuppression increases the risk of acquiring COVID-19 but it could reduce disease severity. Complete immunosuppression withdrawal may not be justified. However, mycophenolate withdrawal or temporary conversion to calcineurin inhibitors or everolimus until disease resolution could be beneficial in hospitalised patients

Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

In liver transplant patients, chronic immunosuppression increases the risk of acquiring COVID-19 but it could reduce disease severity. Com- plete immunosuppression with- drawal may not be justified. However, mycophenolate withdrawal or tem- porary conversion to calcineurin inhibitors or everolimus until disease resolution could be beneficial in hos- pitalised patients